Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Particle shape enhances specificity of antibody-displaying nanoparticles.

Barua S, Yoo JW, Kolhar P, Wakankar A, Gokarn YR, Mitragotri S.

Proc Natl Acad Sci U S A. 2013 Feb 26;110(9):3270-5. doi: 10.1073/pnas.1216893110. Epub 2013 Feb 11.

2.
3.

Novel anti-HER2 monoclonal antibodies: synergy and antagonism with tumor necrosis factor-α.

Ceran C, Cokol M, Cingoz S, Tasan I, Ozturk M, Yagci T.

BMC Cancer. 2012 Oct 4;12:450. doi: 10.1186/1471-2407-12-450.

4.

Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression.

Ballangrud AM, Yang WH, Palm S, Enmon R, Borchardt PE, Pellegrini VA, McDevitt MR, Scheinberg DA, Sgouros G.

Clin Cancer Res. 2004 Jul 1;10(13):4489-97.

5.
6.

Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo.

Barok M, Tanner M, Köninki K, Isola J.

Breast Cancer Res. 2011 Apr 21;13(2):R46. doi: 10.1186/bcr2868.

7.

Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation.

Brockhoff G, Heckel B, Schmidt-Bruecken E, Plander M, Hofstaedter F, Vollmann A, Diermeier S.

Cell Prolif. 2007 Aug;40(4):488-507.

PMID:
17635517
8.

Synergistic targeting of cell membrane, cytoplasm, and nucleus of cancer cells using rod-shaped nanoparticles.

Barua S, Mitragotri S.

ACS Nano. 2013 Nov 26;7(11):9558-70. doi: 10.1021/nn403913k. Epub 2013 Sep 27.

9.

Specific targeting of HER2 overexpressing breast cancer cells with doxorubicin-loaded trastuzumab-modified human serum albumin nanoparticles.

Anhorn MG, Wagner S, Kreuter J, Langer K, von Briesen H.

Bioconjug Chem. 2008 Dec;19(12):2321-31. doi: 10.1021/bc8002452.

PMID:
18937508
10.

Targeted delivery of doxorubicin-utilizing chitosan nanoparticles surface-functionalized with anti-Her2 trastuzumab.

Yousefpour P, Atyabi F, Vasheghani-Farahani E, Movahedi AA, Dinarvand R.

Int J Nanomedicine. 2011;6:1977-90. doi: 10.2147/IJN.S21523. Epub 2011 Sep 14.

11.

Changes in 2-fluoro-2-deoxy-D-glucose incorporation, hexokinase activity and lactate production by breast cancer cells responding to treatment with the anti-HER-2 antibody trastuzumab.

Cheyne RW, Trembleau L, McLaughlin A, Smith TA.

Nucl Med Biol. 2011 Apr;38(3):339-46. doi: 10.1016/j.nucmedbio.2010.09.005. Epub 2010 Dec 3.

PMID:
21492782
12.

Additive effects of trastuzumab and genistein on human breast cancer cells.

Lattrich C, Lubig J, Springwald A, Goerse R, Ortmann O, Treeck O.

Anticancer Drugs. 2011 Mar;22(3):253-61. doi: 10.1097/CAD.0b013e3283427bb5.

PMID:
21160418
14.

Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells.

O'Donovan N, Byrne AT, O'Connor AE, McGee S, Gallagher WM, Crown J.

Invest New Drugs. 2011 Oct;29(5):752-9. doi: 10.1007/s10637-010-9415-5. Epub 2010 Mar 16.

PMID:
20229355
15.

Neural stem cells as a novel platform for tumor-specific delivery of therapeutic antibodies.

Frank RT, Edmiston M, Kendall SE, Najbauer J, Cheung CW, Kassa T, Metz MZ, Kim SU, Glackin CA, Wu AM, Yazaki PJ, Aboody KS.

PLoS One. 2009 Dec 15;4(12):e8314. doi: 10.1371/journal.pone.0008314.

16.

Preparation and characterization of PE38KDEL-loaded anti-HER2 nanoparticles for targeted cancer therapy.

Chen H, Gao J, Lu Y, Kou G, Zhang H, Fan L, Sun Z, Guo Y, Zhong Y.

J Control Release. 2008 Jun 24;128(3):209-16. doi: 10.1016/j.jconrel.2008.03.010. Epub 2008 Mar 19.

PMID:
18450313
17.

Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factors.

Diermeier-Daucher S, Breindl S, Buchholz S, Ortmann O, Brockhoff G.

Cytometry A. 2011 Sep;79(9):684-93. doi: 10.1002/cyto.a.21107. Epub 2011 Jul 22.

18.

Breast tumor cells isolated from in vitro resistance to trastuzumab remain sensitive to trastuzumab anti-tumor effects in vivo and to ADCC killing.

Kute TE, Savage L, Stehle JR Jr, Kim-Shapiro JW, Blanks MJ, Wood J, Vaughn JP.

Cancer Immunol Immunother. 2009 Nov;58(11):1887-96. doi: 10.1007/s00262-009-0700-0. Epub 2009 Apr 2.

PMID:
19340424
19.

Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.

Zhang C, Duan X, Xu L, Ye J, Zhao J, Liu Y.

Breast Cancer Res Treat. 2012 Dec;136(3):739-48. doi: 10.1007/s10549-012-2316-x. Epub 2012 Nov 2.

PMID:
23117856
Items per page

Supplemental Content

Write to the Help Desk